Drugs Made In America Acquisition Corp. (DMAAR) Treasury Shares (2025 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Treasury Shares for 2 consecutive years, with $13.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Treasury Shares fell 41.04% year-over-year to $13.6 million; the trailing twelve-month figure through Jun 2026 stood at $13.6 million (down 41.04% YoY), and the FY2025 full-year result was $23.0 million, changed N/A from the prior year.
• Treasury Shares retreated to $13.6 million in Q2 2026 per DMAAR's latest filing, from $23.0 million in the prior quarter.
• Across five years, Treasury Shares topped out at $23.0 million in Q1 2025 and bottomed at $13.6 million in Q2 2026.